Reviva Pharmaceuticals Holdings Inc recorded a cumulative net loss of $-17 million during 12 month ending in the first quarter 2026.
The Healthcare sector has seen employees of 248 other companies achieving higher income per employee. While Reviva Pharmaceuticals Holdings Inc 's total ranking has deteriorated compared to the previous quarter from 3388 to 3818.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

RVPH Net Income per Employee	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	-1,187,718	-1,418,922	-1,625,479	-1,936,552	-2,065,574
RVPH's Total Ranking	# 3818	# 3388	# 3379	# 3449	# 3044
Seq. Net Income Change	-	-	-	-	-

RVPH Company Profile >> Back to RVPH Efficiency Comparisons >> Compare RVPH Net Income per Employee to its Competitors

RVPH Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 249
Healthcare Sector	# 639
Overall Market	# 3818

Net Income per Employee Statistics
High	Average	Low
$ -608,705	$ -1,904,557	$ -2,872,272
(Dec 31 2021)		(Mar 31 2024)

News about Reviva Pharmaceuticals Holdings Inc Income per employee

Reviva Pharmaceuticals Closes $3 Million Offering Amid Cumulative Net Losses: An Assessment of the Company's Current Situation.

Reviva Pharmaceuticals Holdings, Inc. recently concluded its registered direct offering, raising $3 million through the sale and issuance of common stock shares and accompanying warrants priced at-the-market under Nasdaq rules. The company, a late-stage pharmaceutical firm focused on developing therapies for central nervous system (CNS), inflammatory, and cardiometabolic diseases, has been grappling with financial challenges as revealed by its cumulative net loss of $-40 million in the first quarter of 2024. Additionally, Reviva s overall ranking within the Major Pharmaceutical Preparations industry has slipped, highlighting the need for a careful assessment of the impact of these developments on the company s future.
Assessing the Impact:
1. Registered Direct Offering:
Reviva Pharmaceuticals successfully closed its registered direct offering, generating $3 million in funds. The offering involved the sale and issuance of 1,898,734 shares of the company s common stock, accompanied by warrants to purchase up to the same number of shares. Priced at $1.58 per share, the warrants can be exercised immediately, with an exercise price of $1.455 per share. This infusion of capital is expected to bolster Reviva s financial position and support its ongoing research and development efforts to address unmet medical needs in various therapeutic areas.

Companies with similar Income per Employee for 12 month ending Mar 31 2026, within Healthcare Sector

Income per Employee

Income 12 month ending Mar 31 2026

Number of Employees Mar 31 2026

Date modified: 2026-09-26T07:34:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.